Lukaskrankenhaus

Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

J. Peter Donnelly, Sharon Chen, Carol A. Kauffman et al. · Clinical Infectious Diseases · 2019 · 2.6K citations · Full text

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker et al. · The Lancet Oncology · 2014 · 1.7K citations

Cetuximab Versus Folfiri, Oncology, Clinical Trials +9

A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial

Patrick W. Serruys, Bernard Chevalier, Dariusz Dudek et al. · The Lancet · 2014 · 556 citations · Full text

Percutaneous Coronary Intervention, Absorb Ii, Endovascular Technique +11

Red blood cells express a functional endothelial nitric oxide synthase

Petra Kleinbongard · Blood · 2005 · 550 citations · Full text

Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk

Philip Urban, Roxana Mehran, Róisín Colleran et al. · European Heart Journal · 2019 · 540 citations · Full text